News Releases

Date Title
03/24/2014 Summary ToggleEnanta Pharmaceuticals Announces Data Presentations on Regimens Containing Protease Inhibitor ABT-450 to be Presented at the European Association for the Study of the Liver (EASL) Meeting
03/04/2014 Summary ToggleEnanta Pharmaceuticals Announces New Data Presented on Protease Inhibitor ABT-493 at the 21st Conference on Retroviruses and Opportunistic Infections (CROI)
03/03/2014 Summary TogglePEARL-III Study Results in Patients with Chronic Hepatitis C Presented at the 21st Conference on Retroviruses and Opportunistic Infections (CROI)
02/21/2014 Summary ToggleEnanta Pharmaceuticals to Present at the Cowen and Company 34th Annual Health Care Conference
02/13/2014 Summary ToggleEnanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2013
02/11/2014 Summary ToggleEnanta Pharmaceuticals Announces the Appointment of George S. Golumbeski, Ph.D. to Board of Directors
02/06/2014 Summary ToggleEnanta Pharmaceuticals to Present at the 2014 Leerink Global Healthcare Conference Presentation to be Webcast on February 13, 2014 at 2:15 P.M. ET
02/03/2014 Summary ToggleEnanta Pharmaceuticals Announces the Appointment of Timothy D. Ocain, Ph.D. as Senior Vice President, New Product Strategy and Development
01/31/2014 Summary ToggleEnanta Pharmaceuticals Announces Results from Four All-Oral, Interferon-Free, Phase 3 Studies for the Treatment of Genotype 1 Hepatitis C Virus Infection
01/13/2014 Summary ToggleEnanta Pharmaceuticals Initiates Phase 1 Study of MRSA Infection Candidate EDP-788